Featured Press Releases

Swiss startup Enzian Pharmaceutics is developing a new tablet aimed at enhancing effectiveness and reducing side effects in cancer therapies

Swiss startup Enzian Pharmaceutics is developing a new tablet aimed at enhancing effectiveness and reducing side effects in cancer therapies

FDA Approves Myhibbin™ by Azurity Pharmaceuticals, Inc., a Mycophenolate Mofetil Oral Suspension

FDA Approves Myhibbin™ by Azurity Pharmaceuticals, Inc., a Mycophenolate Mofetil Oral Suspension

  • 06 May 2024

Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and...

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Neurotech Welcomes Industry Veteran Beth Marsh as Chief Commercial Officer

Neurotech Welcomes Industry Veteran Beth Marsh as Chief Commercial Officer

Cellipont Bioservices and Secretome Therapeutics partner for cGMP manufacturing of the Master Cell Bank for their lead asset, STM-01

Cellipont Bioservices and Secretome Therapeutics partner for cGMP manufacturing of the Master Cell Bank for their lead asset, STM-01

Dupixent® outperformed Xolair® in treating CRSwNP with asthma in the first Phase 4 head-to-head trial

Dupixent® outperformed Xolair® in treating CRSwNP with asthma in the first Phase 4 head-to-head trial

VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

  • Intuitive Ventures
  • 19 Nov 2025
FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

  • Arrowhead Pharmaceuticals, Inc.
  • 19 Nov 2025
Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

  • Emulate, Inc. and FUJIFILM Cellular Dynamics
  • 18 Nov 2025
Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

  • Jazz Pharmaceuticals plc
  • 17 Nov 2025
New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

  • Johnson & Johnson
  • 17 Nov 2025
Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

  • Marius Pharmaceuticals LLC
  • 13 Nov 2025
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.